HYEX 最新10-Q变化
将 HYEX 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-05-14 与上一份 10-Q · 2025-11-14
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +12 | −12 | ~11 | 23 |
| 市场风险(第3项) | 文字有新增/删除 | +2 | −2 | ~3 | 17 |
| 控制与程序 | 文字有新增/删除 | +2 | −2 | ~3 | 16 |
| 法律诉讼 | 文字有新增/删除 | +2 | −2 | ~1 | 15 |
| 风险因素 | 文字有新增/删除 | +2 | −2 | ~1 | 13 |
| 其他信息 | 文字有新增/删除 | 0 | −1 | ~1 | 10 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-05-14
Guided by this mission, our first two acquisitions (in 2019 and 2020, respectively) formed our historical operating subsidiaries, BergaMet NA, LLC, which offers nutraceutical heart and immune health products, and UBN, which offers nutraceutical products for brain health. Our GummyUSA acquisition (in…
We had revenues of $1,610,744 for the three months ended March 31, 2026, compared to $931,280 for the three months ended March 31, 2025, an increase of $679,464, or 73%. We expect revenue growth to increase as our direct consumer sales and marketing efforts continue to perform.
Cost of revenue as a percentage of revenues was 39% for the three months ended March 31, 2026, compared to 54% for the three months ended March 31, 2025.
Our general and administrative expenses were $1,317,403 for the three months ended March 31, 2026, compared to $533,833 for the three months ended March 31, 2025, an increase of $783,570, or 147%. In the three months ended March 31, 2026, general and administrative expenses consisted mainly of adver…
Other income (expense) was $128,112 for the three months ended March 31, 2026, compared to $(290,011) for the three months ended March 31, 2025, an increase of $418,123, or 144%. In the three months ended March 31, 2026, other income (expense) consisted of interest expense, net of interest income of…
相对上期删除的文字 · 来源:10-Q · 2025-11-14
Guided by this mission, our first two acquisitions formed our current operating subsidiaries, BergaMet NA, LLC, which offers nutraceutical heart and immune health products, and UBN, which offers nutraceutical products for brain health. Based on published research from third-party sources, we believe…
We had revenues of $917,975 and $2,817,910 for the three and nine months ended September 30, 2025, compared to $744,916 and $2,342,091 for the three and nine months ended September 30, 2024, an increase of $173,058, or 23%, and $475,819, or 20%, respectively. We expect strong growth to increase as o…
Cost of revenue as a percentage of revenues was 51% and 48% for the three and nine months ended September 30, 2025, compared to 19% and 36% for the three and nine months ended September 30, 2024. The reduced cost as a percentage of revenues in the three months ended September 30, 2025 was due to eff…
Our general and administrative expenses were $907,363 and $2,139,630 for the three and nine months ended September 30, 2025, compared to $517,068 and $1,485,945 for the three and nine months ended September 30, 2024, an increase of $390,295, or 75%, and $653,685, or 44%, respectively. In the three m…
Other income (expense) was $64,720 and $(52,565) for the three and nine months ended September 30, 2025, compared to $269,074 and $(404,703) for the three and nine months ended September 30, 2024, a decrease of $204,354, or 76%, and $352,138, or 87%, respectively. In the three months ended September…
市场风险(第3项)
相对上期新增的文字 · 来源:10-Q · 2026-05-14
On March 20, 2026, we issued 20,000 shares of our common stock, restricted in accordance with Rule 144, to two shareholders for services rendered. The issuances were exempt from registration pursuant to Section 4(a)(1) of the Securities Act of 1933, and the shareholders were accredited.
There have been no other events which are required to be reported under this Item.
相对上期删除的文字 · 来源:10-Q · 2025-11-14
There have been no events which are required to be reported under this Item.
Incorporated by reference from our Annual Report on Form 10-K filed with the Commission on August 3, 2021.
控制与程序
相对上期新增的文字 · 来源:10-Q · 2026-05-14
On March 20, 2026, we issued 20,000 shares of our common stock, restricted in accordance with Rule 144, to two shareholders for services rendered. The issuances were exempt from registration pursuant to Section 4(a)(1) of the Securities Act of 1933, and the shareholders were accredited.
There have been no other events which are required to be reported under this Item.
相对上期删除的文字 · 来源:10-Q · 2025-11-14
There have been no events which are required to be reported under this Item.
Incorporated by reference from our Annual Report on Form 10-K filed with the Commission on August 3, 2021.
法律诉讼
相对上期新增的文字 · 来源:10-Q · 2026-05-14
On March 20, 2026, we issued 20,000 shares of our common stock, restricted in accordance with Rule 144, to two shareholders for services rendered. The issuances were exempt from registration pursuant to Section 4(a)(1) of the Securities Act of 1933, and the shareholders were accredited.
There have been no other events which are required to be reported under this Item.
相对上期删除的文字 · 来源:10-Q · 2025-11-14
There have been no events which are required to be reported under this Item.
Incorporated by reference from our Annual Report on Form 10-K filed with the Commission on August 3, 2021.
风险因素
相对上期新增的文字 · 来源:10-Q · 2026-05-14
On March 20, 2026, we issued 20,000 shares of our common stock, restricted in accordance with Rule 144, to two shareholders for services rendered. The issuances were exempt from registration pursuant to Section 4(a)(1) of the Securities Act of 1933, and the shareholders were accredited.
There have been no other events which are required to be reported under this Item.
相对上期删除的文字 · 来源:10-Q · 2025-11-14
There have been no events which are required to be reported under this Item.
Incorporated by reference from our Annual Report on Form 10-K filed with the Commission on August 3, 2021.
其他信息
相对上期删除的文字 · 来源:10-Q · 2025-11-14
Incorporated by reference from our Annual Report on Form 10-K filed with the Commission on August 3, 2021.
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议